Eli Lilly

PERSON Health Care / Pharmaceuticals Momentum 8.1 NORMAL Primary: Spectral Shift

$741B market cap (Indianapolis) manufactures insulin, GLP-1 agonists, and oncology drugs. Market share pressured by generic weight-loss drug competition in India while acquiring CrossBridge Bio for cancer pipeline expansion.

Acquiring CrossBridge Bio for up to $300M to expand oncology portfolio. Competing with Novo Nordisk in weight-loss drug market amid generic erosion in India.
0.00
PSI Score
8.1
Momentum
0%
Confidence
13
Connections
Connected Entities
FDA Novo Nordisk Bloomberg AstraZeneca China Hong Kong United States Merck CEO M&A Donald Trump Jim Cramer India
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-06 2026-04-17 13 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.270
Spectral Shift
831.349
Sentiment-Momentum Divergence
0.000
Source Concentration
0.441
Network Analysis
13 Degree Centrality
Centrality History
2026-04-06 2026-04-17 13 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 8 NEW
Novo Nordisk 7 NEW
Bloomberg 4 NEW
AstraZeneca 3 NEW
China 2 NEW
Hong Kong 2 NEW
United States 2 NEW
Merck 2 NEW
CEO 2 NEW
M&A 2 NEW
Donald Trump 2 NEW
Jim Cramer 2 NEW
India 1 NEW
Article Coverage (0)
DateLaneTitle

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-04-17 ← Intelligence Network